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INTRODUCTION
Central nervous system (CNS) tumors include a broad
spectrum of diseases and reveal various histological, biologi-
cal, and clinical characteristics. Worldwide, cancers of the
brain and nervous system accounted for some 189,000 new
cases and 142,000 deaths annually (1.7% of new cancers;
2.1% of cancer deaths) in the year 2002 (1). Anaplastic astro-
cytomas and glioblastomas account for approximately 38%
of primary CNS tumors; meningiomas and other mesenchy-
mal tumors account for approximately 27%. Other less com-
mon primary CNS tumors include pituitary tumors, schwan-
nomas, CNS lymphomas, oligodendrogliomas, ependymo-
mas, low-grade astrocytomas, and medulloblastomas, in
decreasing orders (2). The recently revised and commonly
used World Health Organization (WHO) classification of
CNS tumors incorporates and interrelates morphology, cyto-
genetics, molecular genetics, and immunologic markers to
be universally applicable and prognostically valid (3, 4). 
Cytogenetic information is essential for the identification of
key genes in tumorigenesis by focusing on specific chromo-
somal sites. To assess the relevance of chromosomal and genetic
abnormalities in CNS tumors, the careful assessment of cyto-
genetic characteristics for individual type of CNS tumors are
needed. Several studies have shown that the majority of menin-
giomas with loss of chromosome 22 carry mutations in the
neurofibromatosis type 2 gene (NF2) on 22q12.2 (5). Accord-
ing to recent statistics, clonal chromosome abnormalities have
been described in approximately 932 CNS tumors from 161
references (6). In spite of the relatively large number of CNS
tumors with clonal chromosome abnormalities, only few stud-
ies have investigated cytogenetic abnormalities for CNS tu-
mors in Korea. Thus, in the present study, 119 CNS tumors
were investigated by conventional karyotypes to characterize
patterns of chromosomal abnormalities involving various CNS
tumors. We also aimed to compare those cytogenetic abnor-
malities and complexities with WHO classification and grade.
MATERIALS AND METHODS
Patients
One hundred nineteen CNS tumors from 110 patients
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Cytogenetic Characterizations of Central Nervous System Tumors: The
First Comprehensive Report from a Single Institution in Korea
The World Health Organization (WHO) classification of central nervous system (CNS)
tumors incorporates morphology, cytogenetics, molecular genetics, and immuno-
logic markers. Despite the relatively large number of CNS tumors with clonal chro-
mosome abnormalities, only few studies have investigated cytogenetic abnormali-
ties for CNS tumors in Korea. Thus, we investigated 119 CNS tumors by conven-
tional G-banded karyotypes to characterize patterns of chromosomal abnormalities
involving various CNS tumors, and 92.4% of them were cultured and karyotyped
successfully. Totally, 51.8% of karyotypable CNS tumors showed abnormal cyto-
genetic results, including neuroepithelial tumors (75.0%), meningeal tumors (71.1%),
pituitary adenomas (4.2%), schwannomas (44.4%), and metastatic tumors (100.0%).
Glioblastomas had hyperdiploid, complex karyotypes, mainly involving chromosomes
Y, 1, 2, 6, 7, 10, 12, 13, and 14. Monosomy 22 was observed in 56.4% of menin-
giomas. There was a significant increase in the frequencies of karyotypic complex-
ity according to the increase of WHO grade between grades I and II (P=0.0422) or
IV (P=0.0101). Abnormal karyotypes were more complex at high-grade tumors, sug-
gesting that the karyotype reflects the biologic nature of the tumor. More detailed
cytogenetic and molecular characterizations of CNS tumors contribute to better diag-
nostic criteria and deeper insights of tumorigenesis, eventually resulting in develop-
ment of novel therapeutic strategies.
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Accepted : 22 July 2008who were diagnosed, operated, and followed up at Depart-
ment of Neurosurgery, Dong-A University Medical Center
between July, 2002 and June, 2007 were studied. The pati-
ent ages at diagnosis ranged between 6 and 79 yr (mean 46
yr); 44 were male and 66 female. Nine patients were ana-
lyzed twice due to recurrent or residual CNS tumors from
two meningiomas and seven astrocytic tumors. Informed
consent was obtained from all of the patients in accordance
with the guidelines of Institutional Review Board.
The revised 2002 WHO classification for CNS tumors
was adopted to formulate the histological analysis (3). The
WHO grading of CNS tumors establishes a malignancy
scale and predicts the biological behavior based on histolog-
ical features of the tumor (3, 4). WHO grade I included two
pilocytic astrocytomas, 41 meningiomas, two craniopharyn-
giomas, three hemangioblastomas, and nine schwannomas.
WHO grade II included five diffuse astrocytomas, two atyp-
ical meningiomas, one oligodendroglioma, one ependymo-
ma, and one hemangiopericytoma. WHO grade III includ-
ed three anaplastic astrocytomas. WHO grade IV contained
16 glioblastomas and one medulloblastoma. Thirty-two tu-
mors including 25 pituitary adenomas, one yolk sac tumor,
three lymphomas, and three metastatic tumors could not be
graded due to the insufficiencies of clinicopathologic data.
Cytogenetic analysis
Cytogenetic analysis was carried out on fresh surgical tumor
specimens, which proved to contain tumors by pathologic
reading of frozen sections. Fresh tissues were mashed and
finely minced to dissociate the cells in Petri dish containing
RPMI 1640 medium with L-glutamine. The cells were in
situ cultured with Chang medium supplemented with L-
glutamine and P-streptomycin at 37℃ in a 5% CO2 atmo-
sphere for 7-10 days. When there were sufficient numbers
of growing cells in the coverslips, the cell cultures were har-
vested. G-banded karyotypes were interpreted according to
the recommendation of the International System for Human
Cytogenetic Nomenclature (ISCN), 2005 (7). Twenty meta-
phases were examined whenever possible. The clonal abnor-
malities were defined as two or more cells with the same
additional whole chromosome or structural chromosome
rearrangement and three or more cells with the same chro-
mosome missing. A complex karyotype was defined as the
presence of three or more abnormalities. 
Statistical methods
Statistical analysis was performed using MedCalc version
9.3 (MedCalc Software, Mariakerke, Belgium). The two-tailed
Fisher’s exact test was used for comparisons of chromosomal
results according to their WHO grades in the CNS tumors.
Pvalue of <0.05 was considered statistically significant.
RESULTS
Successful cultures were obtained on 110 of the 119 CNS
tumors (92.4%) including 23 neuroepithelial tumors (21 as-
trocytic tumors [two pilocytic, five diffuse, and one anaplas-
tic astrocytomas, and 13 glioblastomas], one oligodendoglio-
ma, one ependymoma, and one medulloblastoma), 45 menin-
geal tumors (41 meningiomas [nine meningothelial, seven
fibrous, 16 transitional, one psammomatous, three angioma-
tous, two microcytic, one sclerosing, and two atypical menin-
giomas], one hemangiopericytoma, and three hemangioblas-
tomas), 24 pituitary adenomas, nine schwannomas, two me-
tastatic tumors, one yolk sac tumor, two craniopharyngiomas,
and three lymphomas (one case each NK cell, diffuse large
B cell lymphoma, and Hodgkin disease). Culture failures were
attributed to too tiny sample sizes, delay in sample transfer,
low mitotic activities, and bacterial contaminations. Of the
case successfully cultured, complete karyotypes were obtained
on 108 of 110 CNS tumors (98.2%). Two CNS tumors (one
diffuse astrocytoma and one glioblastoma) were not karyotyped
and interpreted perfectly due to the complex nature of the
abnormalities.
Totally, 57 of 110 CNS tumors (51.8%) had abnormal
karyotypes. Eighteen of 24 neuroepithelial tumors (73.9%),
32 of 45 meningeal tumors (71.1%), one of 24 pituitary
adenomas (4.2%), four of nine schwannomas (44.4%), and
two of two metastatic tumors (100.0%) showed abnormal
karyotypes. All of the others, including one yolk sac tumor,
two craniopharyngiomas, and three lymphomas showed nor-
mal karyotypes. The results are summarized in Table 1. 
According to WHO grades of CNS tumors, 35 of 55 WHO
grade I (63.6%), eight of 10 WHO grade II (80.0%), and
10 of 14 WHO grade IV (71.4%) showed abnormal kary-
otypes (Table 2). In WHO grade III, only one tumor was
interpretable and it showed a normal karyotype. The fre-
quency of cytogenetic abnormalities showed a tendency to
increase according to the change of WHO grade from grade
I to grades II or IV, but not statistically significant. On the
other hand, of the cases with abnormal karyotypes, 11 of 35
WHO grade I (31.4%), six of eight WHO grade II (75.0%),
and eight of 10 WHO grade IV (80.0%) showed complex
karyotypes. Accordingly, there was a significant increase in
the frequencies of karyotypic complexity with respect to the
increase of WHO grade between grades I and II (p=0.0422)
or IV (p=0.0101). There was a tendency to increase between
grades II and IV, but not statistically significant (p>0.05).
Neuroepithelial tumors: astrocytic tumors
Twenty one astrocytic tumors were cultured, and two
anaplastic astrocytomas and three glioblastomas showed the
failure of tissue culture. Fifteen of 21 astrocytic tumors (71.4
%) had abnormal karyotypes (Table 3) and six had normal
karyotypes. Eight cases (38.0%) showed a hyperdiploidy,
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almost tetraploidy or triploidy. Three patients showed a
hypodiploidy, mostly losing Y chromosome. A complex
karyotype with over three abnormalities was seen in nine
cases (42.9%).
Pilocytic astrocytomas (WHO grade I) were studied twice
from one patient due to residual tumors, and all cases showed
abnormal karyotypes. Additional materials attached to band
16q24 were shown to be primary abnormality in this case. 
Five diffuse astrocytomas (WHO grade II) were studied;
in two cases the karyotype was normal, in other two cases
the karyotype was abnormal and in the remaining one case,
the karyotyping was not fully completed because of complex
nature of the abnormality. One case of anaplastic astrocytoma
(WHO grade III) show- ed a normal karyotype.
Thirteen cases of glioblastoma (WHO grade IV) were
studied, and in three cases the karyotype was normal. One
case from resection of a recurrent tumor could not be suc-
cessfully interpreted due to the complex nature. Of the cases
with abnormal cytogenetics, the karyotypes were diploid or
near-diploid in six cases, near-tetraploid in one case, and near-
triploid in two cases. In the majority of cases with abnormal
karyotype, there was a mixture of normal and abnormal
metaphases and only three cases had exclusively abnormal
clonal cells. 
Overall, among the cases with successful karyotypes, numer-
ic changes were predominantly losses of chromosomes Y,
10, 13, and 14, and gains of chromosomes 2 and 12. The
most frequent chromosomal loss was the loss of Y chromo-
some, observed in three cases (23.1%). The most commonly
involved chromosomes, numeric or structural, were chro-
mosome 12, observed in five cases (38.5%). Numeric and/or
structural abnormality other than chromosome 12 involved
chromosomes 1, 6, 7, and 14 in four cases (30.8%), and chro-
mosomes 9, 10, 11, 13, 17, 19, and 22 in three cases (23.1%).
The presence of one or more unidentified marker chromo-
somes was also observed in three cases.
Other neuroepithelial tumors
One oligodendroglioma (Table 3) showed a hypodiploidy
with a loss of X chromosome, an isochromosome for chro-
mosome Xq10, additions to 1p36.3, 9p24, 13q32, 15q22,
17q23, and deletions of 1q25, 2q31, 4q31.1, 10p12, 10q23,
11q22, 16p22, 17q23, 22q13. 
One recurrent ependymoma showed a hyperdiploidy with
a reciprocal translocation between the short arm of chromo-
some 11 and the long arm of chromosome 13, trisomies for
chromosomes X, 1, 2, 3, 5, 8, 9, 13, 15, 18, 19, and 21, and
monosomies for chromosomes 4, 10, 13, 14, and 22 (Table 3).
In one recurrent medulloblastoma, a highly complex hy-
podiploid karyotype with multiple numerical and structural
abnormalities was observed (Table 3). 
Meningeal tumors
Forty-five meningeal tumors (Table 4) were karyotyped,
and in 10 cases the karyotype was normal. Twenty-nine of
39 (74.4%) WHO grade I and all of three (100.0%) WHO
grade II (two atypical meningiomas and one hemangioperi-
cytoma) meningeal tumors showed abnormal karyotypes.
Of the cases with abnormal cytogenetics, the karyotypes
were diploid in six cases, hypodiploid in 20 cases, and hyper-
diploid in six cases. 
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Histologic types
Culture 
success 
(%)
Total 
No.
Chromosome
Abnormal 
(%)
Normal
(%)
Neuroepithelial tumors
Astrocytic tumors
Pilocytic astrocytoma 2 2 (100.0) 2 (100.0) 0 (0.0)
Diffuse astrocytoma 5 5 (100.0) 3 (60.0) 2 (40.0)
Anaplastic astrocytoma  3 1 (33.3) 0 (0.0) 1 (100.0)
Glioblastoma  16 13 (81.3) 10 (71.4) 3 (28.6)
Oligodendroglioma 1 1 (100.0) 1 (100.0) 0 (0.0)
Ependymoma 1 1 (100.0) 1 (100.0) 0 (0.0)
Medulloblastoma  1 1 (100.0) 1 (100.0) 0 (0.0)
Meningeal tumors
Meningioma  43 41 (95.3) 31 (75.6) 10 (24.4)
Hemangiopericytoma  1 1 (100.0) 1 (100.0) 0 (0.0)
Hemangioblastoma  3 3 (100.0) 0 (0.0) 3 (100.0)
Pituitary adenoma 25 24 (96.0) 1 (4.2) 23 (95.8)
Schwannoma 9 9 (100.0) 4 (44.4) 5 (55.6)
Metastatic tumors 3 2 (66.7) 2 (100.0) 0 (0.0)
Yolk sac tumor 1 1 (100.0) 0 (0.0) 1 (100.0)
Craniopharyngioma  2 2 (100.0) 0 (0.0) 2 (100.0)
Lymphomas
Blastic NK cell 1 1 (100.0) 0 (0.0) 1 (100.0)
lymphoma, metastatic
Diffuse large B cell 1 1 (100.0) 0 (0.0) 1 (100.0)
lymphoma
Hodgkin disease       1 1 (100.0) 0 (0.0) 1 (100.0)
Total 119 110 (92.4) 57 (51.8) 53 (48.2)
Table 1. Histologic and cytogenetic findings of 119 central ner-
vous system tumors
*Statistically significant (P=0.0422) compared to WHO grade I by Fish-
er’s exact test; 
� Statistically significant (P=0.0101) compared to WHO
grade I by Fisher’s exact test. 
WHO 
grades
Total 
No.
Culture
success
(%)
Chromosome
Abnormal 
(%)
Normal
(%)
Complexi-
ty (%)
I 57 55 (96.5) 35 (63.6) 20 (36.4) 11 (31.4)
II 10 10 (100.0) 8 (80.0) 2 (20.0) 6 (75.0)*
III 3 1 (33.3) 0 (0.0) 1 (100.0) 0 (0.0)
IV 17 14 (82.4) 10 (71.4) 4 (28.6) 8 (80.0)
�
Not graded 32 30 (93.8) 3 (10.0) 27 (90.0) 0 (0.0)
Table 2. Cytogenetic results according to WHO grades Loss of chromosome 22, which observed in 22 of 39 menin-
giomas (WHO grade I) (56.4%), was the most common
consistent numerical chromosome change. Sole monosomy
22 was observed in seven cases (17.8%). Monosomy 22 with
additional chromosome abnormalities was shown in 12 of
22 meningiomas (54.5%), involving chromosomes X (18.2%),
1 (31.8%), 12 (22.7%), and 20 (18.2%). The most common
secondary chromosome abnormality associated with mono-
somy 22 was chromosome 1, observed in seven cases (31.8%).
Clonal evolutions were found in six patients and unrelated
clones were also noted in one patient. Primary numerical
and/or structural chromosome abnormalities other than mono-
somy 22 were identified in seven patients (17.9%), involv-
ing chromosomes 5 (7.7%), 6 (10.3%), 7 (5.1%), 19 (7.7%),
and 20 (5.1%).
Two atypical meningiomas (WHO grade II) were ana-
lyzed; in one case monosomy 22 with additional abnormali-
ties was observed, in the other case, a reciprocal transloca-
tion between long arms of chromosome 2 and 12, gain of
chromosomes X, 4, and 5 were shown as complex abnor-
malities.  
One hemangiopericytoma (Table 4) showed a hypodiploidy
with a loss of X chromosome. 
Pituitary adenomas, schwannomas and metastatic tumors
Of 24 pituitary adenomas (Table 5) only one, carrying exten-
sive necrosis in histopathology, showed a loss of Y chromo-
some in karyotype. 
In schwannoma, loss of chromosome 22 as a sole abnor-
mality was identified in three of nine cases. Other alterations
involved an addition to 18p11.2 and deletions of 4q26 and
9q34 (Table 6).
As for metastatic tumors, a loss of Y chromosome was found
as the sole chromosome abnormality in two adenocarcinomas,
both metastasized from stomach cancers, presented in Table 7.
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No. Age/sex
Diagnosis
(WHO grade)
Karyotypes
Astrocytic tumors
1 11/F Pilocytic astrocytoma (I)* 46,XX,add(6)(p25),add(16)(q24)[7]/46,XX,add(16)(q24),add(22)(q13)[2]/46,XX[11]
2 11/F Pilocytic astrocytoma (I)* 46,XX,add(6)(p25),add(16)(q24)[20]
3 29/M Diffuse astrocytoma (II) 47,XY,+Y[19]/49,idem,+Y,+6[1]
4 31/M Diffuse astrocytoma (II), 47,XY,+Y,t(1;1)(p31;p36.2),inv(11)(q13q22),add(19)(p13.3)[20]
recurred
5 6/F Diffuse astrocytoma (II) Complex karyotype
6 68/M Glioblastoma (IV) 94,XXYY,t(1;22)(p10;q10)x2,+2,+6,der(7q+)x2,+del(9)(p10),+der(9p+)x2,del(11)(p10),
+12,-13,-13,-14,-19,-20,-20,+2mar[5]/46,X,-Y[5]/46,XY[11]
7 47/F Glioblastoma (IV) 78~84,XXXX,-6,-6,+7,+7,-8,-8,del(9)(p23)x2,-10,-10,der(12q-)x2,-14,-14,-17,-17,add(19q+)x2,
add(22q+)x2[cp11]/41~43,XX,-6,+7,-8,del(9)(p23),-10,der(12q-)x2,-14,-17,add(19q+),
add(22q+)[cp9]
8 47/F Glioblastoma (IV), recurred Complex karyotype
9 64/F Glioblastoma (IV), recurred 70~72,X,-X,-X,+1,+2,del(4)(q31.3),+5,del(6)(q21),del(7)(p13),der(7)t(7;13)(p15;q14),
del(9)(p10),del(9)(p13),-10,i(17)(q10),-18,der(19p+),+r(?),+2mar[cp12]
10 46/M Glioblastoma (IV) 45,X-Y[10]/46,XY[10]
11 47/M Glioblastoma (IV), recurred 46,XY,t(1;13)(p12;q32),der(17p+)[9]/46,XY[2]
12 14/F Glioblastoma (IV) 45,XX,t(3;11)(p10;q10),del(3)(p21),del(5)(q21),-12,add(14p),add(18q)[5]
13 77/F Glioblastoma (IV) 47,XX,+12[2]/46,XX[11]
14 73/M Glioblastoma (IV) 45,X,-Y,t(1;4)(p36.3;q27),del(10)(q23)[3]/46,XY[7]
15 49/M Glioblastoma (IV) 45,X,-Y,t(3;11)(p21;p15),t(10;19)(q22;p13.3)[3]/45,X,-Y,del(6)(q23),del(7)(q22),add(11)
(q23),+mar[2]/46,X,-Y,-13,add(14)(q32),+15,del(18)(q12),add(21)(q22),add(22)(q13),
+mar[2]/44~46,X,-Y,del(12)(p12),add(20)(q13.3)[cp12]/46,XY[2]
Oligodendroglioma
16 42/F Oligodendroglioma (II) 45~46,X,-X,i(X)(q10),t(1;20)(p22;q13.3),add(1)(p36.3),del(1)(q25),del(2)(q31),del(4)(q31.1),
add(9)(p24),del(10)(p12),del(10)(q23),del(11)(q22),add(13)(q32),add(15)(q22),del(16)(q22),
del(17)(q23),add(17)(q23),del(22)(q13)[cp19]/46,XX[1]
Ependymoma
17 50/F Ependymoma (II), recurred 77,XXX,+X,+1,+2,+3,-4,+5,+8,+9,-10,t(11;13)(p15;q22)x2,+12,-13,-14,+15,+18,+19,+20,
+21,-22[20]
Medulloblastoma
18 29/M Medulloblastoma (IV), recurred 41,X,-Y,-3,-4,del(6)(q21),9p+,del(9)(p13),dic(11;?),-13,-13,-14,15p+,-16,-16,-17,-17,-18,
-18,-19,-20,+9mar[9]
Table 3. Cytogenetic abnormalities in neuroepithelial tumors
*, Pilocytic astrocytomas were studied twice from one patient due to residual tumors.DISCUSSION
Cytogenetic information for CNS tumors has been relative-
ly less understandable than the one for hematologic malignan-
cies (8, 9). Although non-random chromosomal alterations
have been identified in various CNS tumors, their clinical
and molecular significance remains unclear. This lack of sig-
nificance is partially due to technical difficulties in culture
and to the karyotypic complexity. A large number of cyto-
genetically well-analyzed data for CNS tumors have still been
required. To the best of our knowledge, this study reports
the first comprehensive cytogenetic aberrations of CNS tumors
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No. Age/sex Histology Karyotype
Meningioma (I)
1 71/F Meningothelial type 46,XX,der(8)t(1;8)(q12;p23)[17]/45,idem,t(1;9)(p10;q10),-22[4]
2 29/F Meningothelial type, recurred 46,XX,inv(6)(p24q21)[5]/46,XX[15]
3 73/F Meningothelial type 42,X,-X,del(1)(p31),-4,-6,der(9)inv(9)(p12q13)c,del(9)(q34),del(14)(q24),dic(17;?)(p12;?),
del(18)(q21),-20,-22,del(22)(q12)[cp5]/46,XX,inv(9)(p12q13)c[15]
4 52/M Meningothelial type 47,XY,+12[4]/46,XY[16]
5 76/F Meningothelial type 47,XX,+7[6]/46,XX[12]
6 39/F Meningothelial type 45,XX,-22[20]
7 63/F Fibrous type 45,XX,-22[12]/45,XX,t(1;21)(p10;p10),-22[4]
8 57/F Fibrous type 45,XX,-22[20]
9 65/F Fibrous type 49,XX,+11,+12,+17,+20,-22[14]
10 74/F Fibrous type 45,XX,-22[14]/45,idem,add(20)(q13.3)[2]
11 37/F Fibrous type 45,XX,-22[22]
12 72/F Fibrous type 44,X,-X,-22[15]
13 49/F Transitional type 45,XX,-22[22]/46,XX[1]
14 44/F Transitional type 45,XX,-22[17]/45,XX,der(13;22)(q10;q10)[3]
15 46/F Transitional type 46,XX,t(1;19)(p10;q10)[20]
16 66/F Transitional type 42,X,-X,-8,-19,-22[18]/46,XX[3]
17 51/F Transitional type 45,XX,-22[20]
18 61/M Transitional type 45,X,-Y,+11,-22[1]/44,idem,-14[6]/46,XY[13]
19 42/F Transitional type 46,XX,del(2)(q31)[16]/46,idem,del(4)(q21q31.3)[1]/46,idem,del(5)(q15q31)[1]/46,idem,
t(6;14)(p12;q24)[1]/46,XX[1]
20 62/M Transitional type 42,XY,-1,der(6)t(1;6)(q12;q13),der(12)t(12;15)(q10;q10),-15,-18,-22[20]
21 63/M Transitional type, recurred 42,XY,der(1)t(1;?)(p12;?),-6,der(12;15)(q10;q10),-18,-22[15]/43,idem,+15[3]/43,idem,
+der(1)t(1;?)[1]/43,idem,+i(1)(q10)[1]
22 47/F Transitional type 45,XX,t(1;14)(p36.1;q11.2),-22[20]
23 68/F Transitional type 45,XX,-22[20]
24 68/F Transitional type 45,XX,-22[11]
25 61/M Transitional type 55,X,-Y,+3,+5,+7,+9,+10,+12,+13,+17,+18,+20,+20,-22[2]/56,idem,+X,i(1)(q10)[7]/
48~56,X,+X,-Y,i(1)(q10),+5,+7,+9,+10,+12,+13,+17,+18,+20,+20,-22[cp10]/46,XY[1]
26 70/F Psammomatous type 46,XX,+20,-22[20]
27 48/M Angiomatous type 45,X,-Y[15]/50~56,XY,+5,+5,+6,+9,+12,+13,+16,+17,+19,+20[cp3]/46,XY[3]
28 63/M Angiomatous type 59,XY,+X,+Y,+3,+5,+10,+12,+13,+14,+15,+17,+19,+20,+20,+21,-22[20]
29 53/F Microcytic type 62,XX,+5,+5,+6,+7,+9,+11,+12,+13,+13,+16,+17,+17,+19,+20,+20,+21[13]
Atypical meningioma (II)
30 69/M Atypical type  40,X,-Y,der(1)t(1;11)(q10;q10),der(6)t(6;19)(p10;q10),-11,-14,-18,-19,-22[6]/39,idem,-12,
+mar[14]
31 56/F Atypical type  46,XX,t(2;12)(q37;q13)[12]/49,XX,+X,+4,+5[1]
Hemangiopericytoma (II)
32 60/F Hemangiopericytoma 45,X,-X[13]/46,XX[7]
Table 4. Cytogenetic abnormalities in meningeal tumors
No. Age/sex Diagnosis Karyotypes
1 47/M Pituitary adenoma 45,X,-Y[6]/46,XY[14]
Table 5. Cytogenetic abnormalities in pituitary adenomas 
No. Age/sex
Diagnosis
(WHO grade)
Karyotypes
1 46/F Schwannoma (I) 45,XX,-22[10]/46,XX[2]
2 43/M Schwannoma (I) 46,XY,add(18)(p11.2)[7]/
46,idem,del(4)(q26)[1]/
46,idem,add(9)(q34)[1]
3 19/F Schwannoma (I) 45,XX,-22[20]
4 43/M Schwannoma (I) 45,XY,-22[15]/46,XY[3]
Table 6. Cytogenetic abnormalities in schwannomasin Korea. In this study, 92.4% of CNS tumors could be suc-
cessfully cultured. Of the cases with successful cultures, 98.2%
of CNS tumors were completely karyotyped. A cytogenetic
analysis may provide an accurate tool for assessing disease risk
in patients with CNS tumors. In addition, these cytogenetic
results may serve as a target for novel therapeutic approach-
es in CNS tumors. 
Cytogenetic abnormalities might result in aggressive dis-
ease behavior in CNS tumors by promoting tumor cell pro-
liferation as likely as in other various types of cancers. WHO
grades II (80.0%) or IV (71.4%) had more frequent karyotype
abnormalities than with grade I (63.6%). In karyotypic com-
plexity according to WHO grades of CNS tumor, there was
a significant increase in the frequencies of karyotypic complex-
ity between grades I and II (P=0.0422) or IV (P=0.0101).
High-grade tumors were more likely to demonstrate cytoge-
netic abnormalities and complexity than low-grade tumors,
suggesting that the karyotype reflects the biologic nature of
the tumor. 
This study might not accurately represent the cytogenetic
abnormalities and complexities according to WHO grades,
because the incidence differs depending on CNS tumors as
well as WHO grades. Besides, WHO grade I tumors were
much more than the others in this study. Therefore, we need
to include other cases beyond WHO grade II, to make more
comprehensive conclusions. 
Astrocytomas and glioblastoma account for over 30% of
all primary brain and CNS tumors (2, 10). Astrocytic tumors
are highly variable tumors and show complex karyotypes,
manifesting multi-step tumorigenesis events. Classic cyto-
genetics of low grade astrocytic tumors (pilocytic and dif-
fuse astrocytomas) are characterized by normal karyotypes
or abnormal karyotypes in the near-diploid range (11). Loss
of Y chromosome is the most frequent event in glioblastoma,
consistent with the results of a survey from the Cancer Genome
Anatomy Project (CGAP) site. Among high-grade astrocy-
tomas (WHO grades III-IV), the most common whole chro-
mosomal gains and losses are as follows: -6, +7, -8, -9, -10,
-13, -14, -17, and -22 (6). 
Recent comparative genomic hybridization (CGH) stud-
ies for gliomas have identified novel regions of change, includ-
ing gains of 1p34-p36, 12p13, and 20q13, amplifications
at 1p36.2, 3q26, 3q27, 7p12, 7q21-q31, 8q24.1, 12p13,
12q13-q15, 17q24, 19q13.2, and 20q13.1, and losses at
1p22, 4q33-q35, 6q16, 6q23-q27, 9p21, 10q25-q26,
13q21.1, and 22q13 (12). The most frequently amplifica-
tion gene in astrocytomas is epidermal growth factor recep-
tor (EGFR at 7p12) gene (13). Classic cytogenetic and CGH
studies of grades II and III astrocytomas demonstrated that
chromosome 7 gains were among the most common genet-
ic alterations (40-66%) (14, 15). Cyclin-dependent kinase 4
(CDK4) and MDM2 at 12q13-15 are amplified in approxi-
mately 10% to 25% of astrocytic tumors (16). 
More recently, Cowell et al. (17) examined four glial cell
lines derived from primary tumors. A bacterial artificial chro-
mosome (BAC) array based CGH enabled the identification
of deletions at the 9p13-p21 region harboring the p16/
CDKN2A gene seen in all four tumors, which were confirmed
with fluorescence in situ hybridizaiton (FISH) assays. Losses
of chromosome 10 are quite frequent in high-grade astrocy-
tomas. Most CGH and FISH studies have identified mono-
somy 10 as independent poor prognosis predictor (18, 19). 
In this study, abnormal karyotypes were seen in 71.4% of
astrocytic tumors, 42.9% of which were complex karyotypes.
The majority of grades I and II astrocytomas showed nor-
mal or abnormal karyotypes with near-diploid and gains of
chromosomes Y and 6. In glioblastomas, this study confirms
and extends prior reports concerning gains of chromosomes
2 and 12 and losses of chromosomes Y, 10, 13, and 14. We
observed common numeric and/or structural abnormality at
chromosome 1, 6, 7, 9, 10, 11, 12, 13, 14, 17, 19, and 22. 
In glioblastoma, tyrosine kinase inhibitors directed at epi-
dermal growth factor receptor (ZD1839, OSI-774) were
being explored as potential treatment modalities. Farnesyl-
transferase inhibitors (R115777), antagonists of the endothe-
lin receptor, and inhibitors of de novo adenosine synthesis
(SDX-102) may be effective. Not only will genetic alterations
offer prognostication, but they will also serve as targets for
directed therapies (20, 21).
In oligodendrogliomas, chromosomal alterations included
deletions of 1p36, 9p, 10, and 22, and gains of chromosome
7, 8q, and 17q (22). The present study corresponds to dele-
tions of 1q24, 10p12, 10q23, and 22q13, and additions to
17q23. 
Ependymomas are well-delineated, moderately cellular
gliomas and are the third most common brain tumors in chil-
dren. The loss of heterozygosity (LOH) studies have identi-
fied LOH of 22q as the most frequent change, seen in approx-
imately 30% of ependymomas (23). In this study, monosomy
22 was found in one ependymoma with hypertriploidy and
multiple numeric changes.
Medulloblastomas (WHO grade IV) are a malignant, inva-
sive embryonal tumor of the cerebellum that occurs primar-
ily in children, having a predominantly neuronal differenti-
ation and a tendency to metastasize through cerebrospinal
fluid pathways. In adulthood, 80% of medulloblastomas
occur in patients with 21 to 40 yr of age. The most frequent
abnormality is loss of 17p, usually through the formation of
an isochromosome, observed in 30% of medulloblastomas
(24). One medulloblastoma in the current report showed
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No. Age/sex Diagnosis Karyotypes
1 75/M Metastatic 45,X,-Y[13]/46,XY[1]
adenocarcinoma
2 36/M Metastatic 45,X,-Y[4]/46,XY[17]
adenocarcinoma
Table 7. Cytogenetic abnormalities in metastatic tumorshighly complex hypodiploid karyotypes with nullosomy for
chromosomes 13, 16, 17, and 18.
Meningiomas are slow growing, mostly benign, WHO
grade I tumors. Although most meningiomas are benign
tumors, as many as 20% exhibit clinically aggressive fea-
tures, leading to considerable morbidity and death (25).
WHO classification of meningiomas includes benign (grade
I), atypical (grade II), and anaplastic (grade III) categories.
Meningiomas were generally thought to progress from low-
grade to high-grade tumors. 
The most frequent cytogenetic abnormality is deletion of
the long arm of chromosome 22 or monosomy 22, observed
in approximately 50-80% of meningiomas (5, 26). In this
study, loss of chromosome 22 was also the most common
change, observed in 56.4% of cases. Cytogenetic and molec-
ular studies have identified the NF2 tumor suppressor gene
at 22q12.1 and its protein product, schwannomin/merlin
(27). Further analysis revealed that the frequency of loss of
chromosome 22 exceeds that of NF2 gene abnormalities (26,
27). This discrepancy of incidence has led to the search for a
second tumor suppressor gene on 22q, including the BAM22
(28), LARGE (29), MN1 (30), and INI1 (31) genes. 
The loss of chromosome 22 associated with other chro-
mosomal aberrations occurs in over 60% of cases. In addi-
tion to the loss of one of sex chromosomes, chromosomes 1,
7, 12, 14, 17, 18, 19, and 20 are also frequent secondary
abnormalities in meningiomas (6). By decreasing order of
frequency, numeric or structural abnormalities of chromo-
somes 1, 20, X, 12, Y, 17, and 18 were observed in the cur-
rent study, consistent with prior reports. 
According to the CGAP site reports of pituitary adenoma
(6), common cytogenetic results are largely diploid with
gains of chromosomes 4, 7, 8, 9, 12, and 20, and losses of
chromosomes 10, 14, 19, and 22. Only one of pituitary ade-
nomas had abnormal karyotypes, loss of Y chromosome in
this study. Its pathogenetic significance still needs further
evaluation.
Schwannomas have also shown chromosomal abnormali-
ties involving chromosome 22q (32). In this study, mono-
somy 22 was shown in three of nine (33.3%).
All patients with adenocarcinomas metastasized from stom-
ach cancers were male and loss of the Y chromosome was
noted. In a study of 37 adenocarcinomas in Barrett’s esopha-
gus and gastric cardia, loss of the Y chromosome seemed a
prominent feature (33).
These cases including oligodendrogliomas, ependymomas,
medulloblastomas, pituitary adenomas, schwannomas, and
adenocarcinomas with abnormal karyotypes are too few for
assessing any recurrent changes and clinical significances.
However it is clear that karyotype complexity is far greater
in high grade than in lower grades of CNS tumors, even in
these types.
In conclusion, we describe cytogenetic results for 110 CNS
tumors cultured and karyotyped successfully. Fifty-seven of
110 CNS tumors (51.8%) showed abnormal karyotypes. Com-
mon aberrations of chromosomes associated with oncogenes
or tumor suppressor genes in the previous reports could be
defined in the various type of CNS tumors. To the best of
our knowledge, this is the first comprehensive cytogenetic
study of CNS tumors in Korea. Abnormal karyotypes are more
complex at high-grade tumors, suggesting that the karyotype
reflects the biologic nature of the tumor and has clinically
prognostic implications as WHO grade. The data presented
in this study would be useful as a guide for further advanced
molecular studies. More detailed cytogenetic and molecular
characterizations of CNS tumors may contribute to better
diagnostic criteria and deeper insights of tumorigenesis, even-
tually resulting in development of novel therapeutic strategies.
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